HC Wainwright reaffirmed their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Free Report) in a report issued on Friday,Benzinga reports. The brokerage currently has a $4.00 price target on the biopharmaceutical company's stock.
A number of other equities analysts have also recently issued reports on LXRX. Needham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. Piper Sandler lowered their price target on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Leerink Partners reissued a "market perform" rating and set a $1.00 price objective (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. Leerink Partnrs cut Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Finally, StockNews.com started coverage on Lexicon Pharmaceuticals in a research note on Friday. They set a "sell" rating on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $3.67.
Get Our Latest Research Report on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Price Performance
LXRX traded down $0.11 during trading on Friday, hitting $0.46. 79,712,677 shares of the stock traded hands, compared to its average volume of 5,905,000. The business has a 50 day moving average price of $0.61 and a 200 day moving average price of $0.99. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. Lexicon Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $2.45. The company has a market cap of $113.47 million, a price-to-earnings ratio of -0.61 and a beta of 1.04.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $26.55 million during the quarter, compared to the consensus estimate of $6.48 million. Equities research analysts forecast that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Lexicon Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC raised its holdings in Lexicon Pharmaceuticals by 28.9% during the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company's stock worth $78,291,000 after purchasing an additional 11,179,919 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Lexicon Pharmaceuticals by 4.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company's stock worth $2,225,000 after purchasing an additional 58,147 shares in the last quarter. XTX Topco Ltd acquired a new position in Lexicon Pharmaceuticals in the third quarter valued at approximately $126,000. Swiss National Bank boosted its holdings in shares of Lexicon Pharmaceuticals by 34.4% during the 4th quarter. Swiss National Bank now owns 426,600 shares of the biopharmaceutical company's stock worth $315,000 after buying an additional 109,100 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Lexicon Pharmaceuticals by 8.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company's stock valued at $5,534,000 after acquiring an additional 273,436 shares in the last quarter. Institutional investors and hedge funds own 74.70% of the company's stock.
Lexicon Pharmaceuticals Company Profile
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Further Reading
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
